Genomic Considerations in the Treatment of Thyroid Carcinoma. Hattum CJ, Elsey RJ, Meissner T, Spanos WC. JCO Oncol Pract. 2024;20(7):873-875. https://www.doi.org/10.1200/OP.24.00198

Polycystic ovary syndromeStener-Victorin E, Teede H, Norman RJ, et al. PNat Rev Dis Primers. 2024 Apr 18;10(1):27.https://www.doi.org/10.1038/s41572-024-00511-3

Graves disease: latest understanding of pathogenesis and treatment options. Nat Rev Endocrinol. Lanzolla G, Marinò M, Menconi F. Published online July 22, 2024. doi:10.1038/s41574-024-01016-5

What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed MediatorsMulders MCF, de Herder WW, Hofland J.Endocr Rev. 2024 May 7;45(3):351-360. doi: 10.1210/endrev/bnad035

Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Mullen N, Curneen J, Donlon PT, et al.Endocr Rev. 2024 Jan 4;45(1):125-170. doi: 10.1210/endrev/bnad026

Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal HyperplasiaKyriakie Sarafoglou, Mimi S Kim, Maya Lodish, et al.N Engl J Med. 2024 Jun 2. doi: 10.1056/NEJMoa2404655

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guidelineEystein S Husebye, Frederik Castinetti, et al. Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21. https://doi.org/10.1530/EJE-22-0689

Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statementMargaret C S Boguszewski, Cesar L Boguszewski , et al. Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52. https://doi.org/10.1530/EJE-21-1186

Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International WorkshopJohn P Bilezikian 1, Aliya A Khan, et al. J Bone Miner Res. 2022 Nov;37(11):2293-2314. https://doi.org/10.1002/jbmr.4677

Genetics of Cushing’s disease: from the lab to clinical practiceMarily Theodoropoulou , Martin Reincke Pituitary. 2022 Oct;25(5):689-692. https://doi.org/10.1007/s11102-022-01253-9